Yozma Group Korea

Betterteem is a predictive and prescriptive AI platform that enables businesses to predict unwanted employee resignations with AI. Betterteem's AI-driven prediction resulted in an 18% increase in employee retention and a 41% increase in productivity in 2023, saving clients over US$18 million in backfill hiring costs and lost productivity.

INGRADIENT is a medical AI data labeling company that develops MediLabel to process data for doctors and researchers. The platform labels large-scale medical images quickly by learning user labeling patterns and can visually predict labeling outputs, enabling medical staff and hospitals to save time and reduce costs in the data labeling process.

CK Regeon is a biotechnology company focused on improving human health through innovative drug development. The company specializes in creating small molecules and peptides designed to treat various metabolic disorders. Its research targets specific diseases such as obesity, diabetes, and non-alcoholic steatohepatitis, while also addressing conditions related to hair growth and wound healing. By developing targeted compounds, CK Regeon aims to provide effective therapeutic solutions that enhance the quality of life for patients suffering from these health issues.

HashBrand is a blockchain technology that provides an activation system.

Mirae SCI is a global company based in Cheongju, South Korea, that specializes in the manufacturing of photoconductor drums. The company operates in several sectors, including chemical materials, construction materials, and biotechnology transfer. Its diverse product portfolio includes polypropylene, SAN resin, polystyrene, alkyd resin, and butyl rubber. Mirae SCI is committed to innovation and challenges, striving to create a better world through its various business endeavors.

Syntekabio, Inc. is a bioinformatics company based in Daejeon, South Korea, founded in 2009. The firm specializes in genome analysis and the integration of bio data, utilizing advanced algorithms to create personal genome maps that facilitate disease prevention and the development of customized medications. Syntekabio also offers a technology for collecting and integrating decrypted whole genome data, which is instrumental in analyzing diseases, including rare conditions. Their MAHA supercomputer significantly reduces data-processing costs and enhances genome-based diagnostics. The company focuses on gene-related research and technology development, leveraging a genome big data platform and artificial intelligence for drug development and genetic analysis.